BRAIN and NERVE－神経研究の進歩70巻4号

2018年04月発行

増大特集 Antibody Update 2018

P/Q型カルシウムチャネル抗体とランバート・イートン筋無力症候群

著者： 北之園寛子¹ 白石裕一¹ 本村政勝¹²

所属機関： ¹長崎大学病院脳神経内科 ²長崎総合科学大学医療工学コース

ページ範囲：P.341 - P.355

文献概要

Lambert-Eaton筋無力症候群（LEMS）は，シナプス前終末からのアセチルコリンの放出障害により，四肢筋力低下，腱反射低下，および，自律神経障害を呈する神経筋接合部・自律神経の自己免疫疾患である。LEMS患者の半数以上が悪性腫瘍，主に小細胞肺癌（SCLC）を合併する傍腫瘍性症候群でもある。SCLCを含む神経内分泌腫瘍に対する腫瘍免疫で自己抗体が生じ，シナプス前終末の活性帯に局在するP/Q型カルシウムチャネルをdown-regulationさせることが，LEMSの病態機序と考察される。

参考文献

1)辻畑光宏: 神経筋接合部の微細構造. Clinical Neuroscience 26: 959-961, 2008

2)Takamori M: Structure of the neuromuscular junction: function and cooperative mechanisms in the synapse. Ann N Y Acad Sci 1274: 14-23, 2012

3)Titulaer MJ, Lang B, Verschuuren JJ: Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 10: 1098-1107, 2011

4)本村政勝, 福田　卓: Lambert-Eaton筋無力症候群. Brain Nerve 63: 745-754, 2011

5)Motomura M, Nakata R, Shiraishi H: Lambert-Eaton myasthenic syndrome: clinical review. Clin Exp Neuroimmun 7: 238-245, 2016

6)Anderson HJ, Churchill-Davidson HC, Richardson AT: Bronchial neoplasm with myasthenia; prolonged apnoea after administration of succinylcholine. Lancet 265: 1291-1293, 1953

7)Lambert EH, Eaton LM, Rooke ED: Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol 187: 612-613, 1956

8)Lang B, Newsom-Davis J, Wray D, Vincent A, Murray N: Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 2: 224-226, 1981

9)Newsom-Davis J, Murray N, Wray D, Lang B, Prior C, et al: Lambert-Eaton myasthenic syndrome: electrophysiological evidence for a humoral factor. Muscle Nerve 5(9S): S17-S20, 1982

10)Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A: Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci U S A 80: 7636-7640, 1983

11)Prior C, Lang B, Wray D, Newsom-Davis J: Action of Lambert-Eaton myasthenic syndrome IgG at mouse motor nerve terminals. Ann Neurol 17: 587-592, 1985

12)Roberts A, Perera S, Lang B, Vincent A, Newsom-Davis J: Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature 317: 737-739, 1985

13)Lang B, Newsom-Davis J, Peers C, Prior C, Wray DW: The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse. J Physiol 390: 257-270, 1987

14)Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J: An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 58: 85-87, 1995

15)Lennon VA, Kryzer TJ, Griesmann GE, O'Suilleabhain PE, Windebank AJ, et al: Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 332: 1467-1474, 1995

16)Wirtz PW, van Dijk JG, van Doorn PA, van Engelen BG, van der Kooi AJ, et al: The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands. Neurology 63: 397-398, 2004

17)Titulaer MJ, Lang B, Verschuuren JJ: Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 10: 1098-1107, 2011

18)Abenroth DC, Smith AG, Greenlee JE, Austin SD, Clardy SL: Lambert-Eaton myasthenic syndrome: epidemiology and therapeutic response in the national veterans affairs population. Muscle Nerve 56: 421-426, 2017

19)O'Neill JH, Murray NM, Newsom-Davis J: The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111: 577-596, 1988

20)Nakao YK, Motomura M, Fukudome T, Fukuda T, Shiraishi H, et al: Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 59: 1773-1775, 2002

21)Titulaer MJ, Wirtz PW, Kuks JB, Schelhaas HJ, van der Kooi AJ, et al: The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. J Neuroimmunol 201-202: 153-158, 2008

22)中島一郎, 菊地昭夫, 小野寺淳一, 志賀裕正, 藤原一男, 他: 著明なるい痩を呈した17歳発症のLambert-Eaton症候群の1例. 臨床神経37: 402-406, 1997

23)Morimoto M, Osaki T, Nagara Y, Kodate M, Motomura M, et al: Thymoma with Lambert-Eaton myasthenic syndrome. Ann Thorac Surg 89: 2001-2003, 2010

24)Oyaizu T, Okada Y, Sagawa M, Yamakawa K, Kuroda H, et al: Lambert-Eaton myasthenic syndrome associated with an anterior mediastinal small cell carcinoma. J Thorac Cardiovasc Surg 121: 1005-1006, 2001

25)Siau RT, Morris A, Karoo RO: Surgery results in complete cure of Lambert-Eaton myasthenic syndrome in a patient with metastatic Merkel cell carcinoma. J Plast Reconstr Aesthet Surg 67: e162-e164, 2014［doi: 10.1016/j.bjps.2014.03.014］

26)Ferlito A, Rinaldo A, Bishop JA, Hunt JL, Vander Poorten V, et al: Paraneoplastic syndromes in patients with laryngeal neuroendocrine carcinomas: clinical manifestations and prognostic significance. Eur Arch Otorhinolaryngol 273: 533-536, 2016

27)Nalbantoglu M, Kose L, Uzun N, Gunduz A, Hallac M, et al: Lambert-Eaton myasthenic syndrome associated with thymic neuroendocrine carcinoma. Muscle Nerve 51: 936-938, 2015

28)Iyer JG, Parvathaneni K, Bhatia S, Tarabadkar ES, Blom A, et al: Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): a case series of 8 patients highlighting different clinical manifestations. J Am Acad Dermatol 75: 541-547, 2016

29)Pavolucci L, Giannini G, Giannoccaro MP, Foschini MP, Lang B, et al: Paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenia in a patient with merkel cell carcinoma and voltage-gated calcium channel antibodies. Muscle Nerve 56: 998-1000, 2017

30)Takasugi J, Shimamura M, Koda T, Kishikawa T, Hanamoto A, et al: A case of paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenic syndrome associated with neuroendocrine carcinoma of the oropharynx. Intern Med 57: 587-590, 2017

31)Catterall WA: Signaling complexes of voltage-gated sodium and calcium channels. Neurosci Lett 486: 107-116, 2010

32)Zamponi GW, Striessnig J, Koschak A, Dolphin AC: The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol Rev 67: 821-870, 2015

33)Takamori M, Iwasa K, Komai K: Antibodies to synthetic peptides of the alpha1A subunit of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. Neurology 48: 1261-1265, 1997

34)Takamori M, Iwasa K, Komai K: Antigenic sites of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 841: 625-635, 1998

35)Iwasa K, Takamori M, Komai K, Mori Y: Recombinant calcium channel is recognized by Lambert-Eaton myasthenic syndrome antibodies. Neurology 54: 757-759, 2000

36)Motomura M, Lang B, Johnston I, Palace J, Vincent A, et al: Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 147: 35-42, 1997

37)el Far O, Marquèze B, Leveque C, Martin-Moutôt N, Lang B, et al: Antigens associated with N- and L-type calcium channels in Lambert-Eaton myasthenic syndrome. J Neurochem 64: 1696-1702, 1995

38)Pinto A, Gillard S, Moss F, Whyte K, Brust P, et al: Human autoantibodies specific for the alpha1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons. Proc Natl Acad Sci U S A 95: 8328-8333, 1998

39)Spillane J, Ermolyuk Y, Cano-Jaimez M, Lang B, Vincent A, et al: Lambert-Eaton syndrome IgG inhibits transmitter release via P/Q Ca2+ channels. Neurology 84: 575-579, 2015

40)Tsujihata M, Kinoshita I, Mori M, Mori K, Shirabe S, et al: Ultrastructural study of the motor end-plate in botulism and Lambert-Eaton myasthenic syndrome. J Neurol Sci 81: 197-213, 1987

41)吉村俊朗, 本村政勝, 吉村俊祐, 辻畑光宏: 診断と鑑別診断Motor point筋生検. Clinical Neuroscience 32: 1018-1019, 2014

42)Tsujihata M, Ito H, Satoh A, Yoshimura T, Motomura M, et al: Semiquantitative measurement of acetylcholine receptor at the motor end-plate in myasthenia gravis. Intern Med 40: 376-381, 2001

43)Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, et al: Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 57: 289-293, 2005

44)Satoyoshi E, Kowa H, Fukunaga N: Subacute cerebellar degeneration and Eaton-Lambert syndrome with bronchogenic carcinoma. A case report. Neurology 23: 764-768, 1973

45)大久保和昭, 大石清澄, 本村政勝, 酒井宏一郎, 辻畑光宏, 他: Lambert-Eaton myasthenic syndrome（LEMS）とsubacute cerebellar degeneration（SCD）を伴った肺小細胞癌の1例　本邦報告例の臨床的検討. 脳と神経46: 285-289, 1994

46)Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, et al: Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 120: 1279-1300, 1997

47)Fukuda T, Motomura M, Nakao Y, Shiraishi H, Yoshimura T, et al: Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 53: 21-28, 2003

48)Houzen H, Hattori Y, Kanno M, Kikuchi S, Tashiro K, et al: Functional evaluation of inhibition of autonomic transmitter release by autoantibody from Lambert-Eaton myasthenic syndrome. Ann Neurol 43: 677-680, 1998

49)Kanzato N, Motomura M, Suehara M, Arimura K: Lambert-Eaton myasthenic syndrome with ophthalmoparesis and pseudoblepharospasm. Muscle Nerve 22: 1727-1730, 1999

50)Ueda T, Kanda F, Kobessho H, Hamaguchi H, Motomura M: “Dropped head syndrome” caused by Lambert-Eaton myasthenic syndrome. Muscle Nerve 40: 134-136, 2009

51)Barr CW, Claussen G, Thomas D, Fesenmeier JT, Pearlman RL, et al: Primary respiratory failure as the presenting symptom in Lambert-Eaton myasthenic syndrome. Muscle Nerve 16: 712-715, 1993

52)Merino-Ramírez MÁ, Bolton CF: Review of the diagnostic challenges of Lambert-Eaton syndrome revealed through three case reports. Can J Neurol Sci 43: 635-647, 2016

53)O'Suilleabhain P, Low PA, Lennon VA: Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates. Neurology 50: 88-93, 1998

54)Gökçal E, Gürsoy AE, Asil T, Ertaş M: Lambert-Eaton myasthenic syndrome with a twenty-three-year delay in diagnosis. Noro Psikiyatr Ars 54: 189-190, 2017

55)福留隆泰, 吉村俊祐, 白石裕一, 本村政勝: Lambert-Eaton筋無力症候群: update, 神経内科87: 404-410, 2017

56)畑中裕己, 園生雅弘: Lambert-Eaton myasthenic syndromeにおける神経反復刺激試験. 臨床脳波51: 653-659, 2009

57)幸原伸夫, 川本未知, 石井淳子, 村瀬　翔: Lambert-Eaton筋無力症候群. 臨床神経生理44: 28-35, 2016

58)McKasson M, Clardy SL, Clawson SA, Hill KE, Wood B, et al: Voltage-gated calcium channel autoimmune cerebellar degeneration: case and study of cytotoxicity. Neurol Neuroimmunol Neuroinflamm 3: e222, 2016［doi: 10.1212/NXI.0000000000000222］

59)Suenaga A, Shirabe S, Nakamura T, Motomura M, Tsujihata M, et al: Specificity of autoantibodies react with omega-conotoxin MVIIC-sensitive calcium channel in Lambert-Eaton myasthenic syndrome. Muscle Nerve 19: 1166-1168, 1996

60)Lang B, Waterman S, Pinto A, Jones D, Moss F, et al: The role of autoantibodies in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 841: 596-605, 1998

61)Nakao YK, Motomura M, Suenaga A, Nakamura T, Yoshimura T, et al: Specificity of omega-conotoxin MVIIC-binding and -blocking calcium channel antibodies in Lambert-Eaton myasthenic syndrome. J Neurol 246: 38-44, 1999

62)丸田高広: Lambert-Eaton筋無力症候群におけるトキシン結合阻害型抗電位依存性カルシウムチャネル抗体. 金沢大学十全医学会雑誌107: 547-553, 1998

63)Takamori M, Takahashi M, Yasukawa Y, Iwasa K, Nemoto Y, et al: Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome. J Neurol Sci 133: 95-101, 1995

64)Takamori M, Motomura M, Fukudome T, Yoshikawa H: Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders. Eur J Neurol 14: 1230-1235, 2007

65)Berger B, Dersch R, Ruthardt E, Rasiah C, Rauer S, et al: Prevalence of anti-SOX1 reactivity in various neurological disorders. J Neurol Sci 369: 342-346, 2016

66)Takamori M, Hamada T, Komai K, Takahashi M, Yoshida A: Synaptotagmin can cause an immune-mediated model of Lambert-Eaton myasthenic syndrome in rats. Ann Neurol 35: 74-80, 1994

67)Takamori M, Maruta T, Komai K: Lambert-Eaton myasthenic syndrome as an autoimmune calcium-channelopathy. Neurosci Res 36: 183-191, 2000

68)Sioka C, Fotopoulos A, Kyritsis AP: Paraneoplastic neurological syndromes and the role of PET imaging. Oncology 78: 150-156, 2010

69)Wirtz PW, Lang B, Graus F, van den Maagdenberg AM, Saiz A, et al: P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol 164: 161-165, 2005

70)Maddison P, Newsom-Davis J, Mills KR, Souhami RL: Favourable prognosis in Lambert-Eaton myasthenic syndeome and small-cell lung carcinoma. Lancet 353: 117-118, 1999

71)Maddison P, Lang B: Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer. J Neuroimmunol 201-202: 159-162, 2008

72)Maddison P, Gozzard P, Grainge MJ, Lang B: Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 88: 1334-1339, 2017

73)Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, et al: Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 26: 4276-4281, 2008

74)Titulaer MJ, Verschuuren JJ: Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. Ann N Y Acad Sci 1132: 129-134, 2008

75)Wirtz PW, Willcox N, van der Slik AR, Lang B, Maddison P, et al: HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol 159: 230-237, 2005

76)AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine: Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome. Muscle Nerve 24: 1239-1247, 2001

77)中村龍文, 本村政勝: 神経系疾患Lambert-Eaton筋無力症候群. 日本臨牀59（増刊8）: 629-636, 2001

78)Oh SJ, Kurokawa K, Claussen GC, Ryan HF Jr: Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 32: 515-520, 2005

79)Tsuda E, Imai T, Matsumura A, Hisahara S, Nonaka M, et al: Thyrotoxic myopathy mimicking myasthenic syndrome associated with thymic hyperplasia. Intern Med 47: 445-447, 2008

80)松本理器, 本村政勝, 吉村俊朗, 幸原伸夫, 加藤智信: Lambert-Eaton筋無力症候群型の神経筋伝達障害を示した重症筋無力症—血清自己抗体と神経筋接合部生検の有用性. 臨床神経39: 531-537, 1999

81)Oh SJ: Myasthenia gravis Lambert-Eaton overlap syndrome. Muscle Nerve 53: 20-26, 2016

82)Herrmann DN, Horvath R, Sowden JE, Gonzalez M, Sanchez-Mejias A, et al: Synaptotagmin 2 mutations cause an autosomal-dominant form of Lambert-Eaton myasthenic syndrome and nonprogressive motor neuropathy. Am J Hum Genet 95: 332-339, 2014

83)Newsom-Davis J: A treatment algorithm for Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 841: 817-822, 1998

84) Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, et al: Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17: 893-902, 2010

85)Evoli A, Liguori R, Romani A, Mantegazza R, Di Muzio A, et al: Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management. Neurol Sci 35: 515-520, 2014

86)Keogh M, Sedehizadeh S, Maddison P: Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2: CD003279, 2011［doi: 10.1002/14651858.CD003279］

87)Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT: Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 78: 1009-1015, 2012

88)谷口　彰, 北川長生, 木田博隆: Lambert-Eaton症候群6例の臨床症状と治療効果の検討. 神経治療17: 33-38, 2000

89)Oh SJ, Sieb JP: Update on amifampridine as a drug of choice in Lambert-Eaton myasthenic syndrome. US Neurology 10: 83-89, 2014

90)McEvoy KM, Windebank AJ, Daube JR, Low PA: 3,4-diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 321: 1567-1571, 1989

91)Sanders DB, Massey JM, Sanders LL, Edwards LJ: A randomized trial of 3,4-diaminopyridine in Lambert-Eaton syndrome. Neurology 54: 603-607, 2000

92)Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, Alsharabati M, Dimachkie M, et al: Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve 53: 717-725, 2016

93)Portaro S, Brizzi T, Sinicropi S, Cacciola A, De Cola MC, et al: Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: case reports. Medicine (Baltimore) 96: e7839, 2017［doi: 10.1097/MD.0000000000007839］

94)Tarr TB, Malick W, Liang M, Valdomir G, Frasso M, et al: Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome. J Neurosci 33: 10559-10567, 2013

95)Streib EW, Rothner AD: Eaton-Lambert myasthenic syndrome: long-term treatment of three patients with prednisone. Ann Neurol 10: 448-453, 1981

96)Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, et al: Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 47: 678-683, 1996

97)Takata T, Koide S, Ogata K, Motomura M, Yoshimura T, et al: Lambert-Eaton myasthenic syndrome associated with idiopathic thrombocytopenic purpura and diffuse panbronchiolitis: long-term remission after a course of intravenous immunoglobulin combined with low-dose prednisolone. Am J Med Sci 318: 353-355, 1999

98)Okada A, Koike H, Nakamura T, Motomura M, Sobue G: Efficacy of intravenous immunoglobulin for treatment of Lambert-Eaton myasthenic syndrome without anti-presynaptic P/Q-type voltage-gated calcium channel antibodies: a case report. Neuromuscul Disord 25: 70-72, 2015

99)Motomura M, Hamasaki S, Nakane S, Fukuda T, Nakao YK: Apheresis treatment in Lambert-Eaton myasthenic syndrome. Ther Apher 4: 287-290, 2000

100)Dau PC, Denys EH: Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. Ann Neurol 11: 570-575, 1982

101)姉崎利治, 本村政勝, 中村龍文, 本間義章: Lambert-Eaton症候群患者における血液浄化療法と抗電位依存性カルシウム・チャネル抗体価の変動の検討. 神経治療14: 465-468, 1997

102)Pellkofer HL, Voltz R, Kuempfel T: Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve 40: 305-308, 2009

103)Maddison P, McConville J, Farrugia ME, Davies N, Rose M, et al: The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 82: 671-673, 2011

104)Mantegazza R, Meisel A, Sieb JP, Le Masson G, Desnuelle C, et al: The European LEMS registry: baseline demographics and treatment approaches. Neurol Ther 4: 105-124, 2015

105)Titulaer MJ, Maddison P, Sont JK, Wirtz PW, Hilton-Jones D, et al: Clinical Dutch-English Lambert-Eaton myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol 29: 902-908, 2011

106)中村さやか, 河岸由紀男, 加藤慎平, 辻　博, 高川　清, 他: 無治療で長期生存したLambert-Eaton症候群合併肺小細胞癌の1例. 日呼吸会誌48: 918-922, 2010